All had been treated previously with at least one type
of androgen deprivation therapy and had rising levels of prostate specific antigen (PSA), a blood marker for prostate cancer, and radiographic evidence their cancers were becoming resistant.
Not exact matches
«A significant number
of advanced prostate cancer patients treated with a chemical castration therapy called
androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor
of Cancer Biology.
Denmeade says the combination
of drugs that block testosterone production and receptors, called
androgen deprivation therapy, may make prostate cancer more aggressive over time by enabling prostate cancer cells to subvert attempts to block testosterone receptors.
Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field
of applicability than simply in very localised and low risk tumours when combined with other techniques — in this case,
androgen deprivation therapy and external bean radiation therapy.»
«There has been a groundswell
of interest in the idea
of reversing resistance to
androgen deprivation therapy.
Twenty - two patients with elevated prostate - specific antigen and biopsy - proven prostate carcinoma who underwent MRI
of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated with
androgen deprivation, radiation therapy, or both, and a Gleason - matched control group who had not received such therapy.
Preliminary results
of a study
of patients with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to
androgen deprivation and radiation therapy, according to a team
of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston.
The research teams, led by Nima Sharifi, M.D.,
of the Cleveland Clinic Lerner Research Institute, studied the role
of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following
androgen deprivation therapy (ADT).
Androgen deprivation therapy is a powerful tool against prostate cancer, and more and more men are opting for the treatment as a growing array
of hormone - based therapies become available.
A new Moffitt Cancer Center study indicated that men who are on
androgen deprivation therapy have greater odds
of experiencing impaired cognitive function.
«The risk
of cognitive impairment should be considered when deciding whether or not to receive
androgen deprivation therapy for prostate cancer,» said Brian Gonzalez, Ph.D., a postdoctoral fellow in the Health Outcomes and Behavior Program at Moffitt.
Androgen deprivation - induced senescence promotes outgrowth of androgen - refractory prostate cance
Androgen deprivation - induced senescence promotes outgrowth
of androgen - refractory prostate cance
androgen - refractory prostate cancer cells.
Long - term follow - up
of a large phase III study showed that chemohormonal therapy involving docetaxel added to
androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.
A significant fraction
of advanced PCa treated with
androgen deprivation therapy experience relentless progression to lethal metastatic castration - resistant prostate cancer (mCRPC).
Modulation
of protease expression in prostate cancer cells after
androgen deprivation.
Treatment with an investigational
androgen receptor inhibitor significantly delayed the development
of metastasis in patients with prostate cancer that had become resistant to standard
androgen -
deprivation therapy.
A second phase 3 study presented Sunday found that adding radiation to hormone therapy, also known as
androgen -
deprivation therapy (ADT) in patients with locally advanced or high - risk prostate cancer reduced the seven - year risk
of dying by 43 percent compared to treating with hormone therapy alone.
Two clinical trials
of intermittent versus continuous
androgen deprivation found that intermittent therapy reduced some
of the side effects
of hormone therapy, including those involving sexual function.
Researchers have investigated whether a technique called intermittent
androgen deprivation can improve the effectiveness
of hormone therapy for prostate cancer — that is, whether it delays the development
of hormone resistance.